Market Overview:
The Inhaled Nitric Oxide Market is experiencing steady expansion, driven by Growing Prevalence of Respiratory Diseases in Newborns, Rising Geriatric Population and Increasing Investments in Advanced Healthcare Infrastructure. According to IMARC Group’s latest research publication, “Inhaled Nitric Oxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034“, The global inhaled nitric oxide market size was valued at USD 1,059.4 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 1,737.3 Million by 2034, exhibiting a CAGR of 5.65% from 2026-2034.
This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.
Download a sample PDF of this report: https://www.imarcgroup.com/inhaled-nitric-oxide-market/requestsample
Our Report Includes:
- Market Dynamics
- Market Trends and Outlook
- Competitive Analysis
- Industry Segmentation
- Strategic Recommendations
Growth Factors in the Inhaled Nitric Oxide Industry:
- Growing Prevalence of Respiratory Diseases in Newborns
Increasing prevalence of respiratory and other illnesses in neonates and infants is the key growth driver for the global inhaled nitric oxide (iNO) market․ Inhaled nitric oxide therapy is indicated for the treatment of premature neonates with hypoxic respiratory failure and pulmonary hypertension who fail conventional treatment․ The use of nitric oxide can improve oxygen saturation in the blood and allow ECMO to be used․ According to the National Institutes of Health (NIH)‚ lower respiratory infections account for 37․8 million annual cases‚ 501‚910 deaths‚ and 44․8 million disability-adjusted life years (DALYs) worldwide in the population under the age of five․ As the rate of premature birth has increased‚ the number of hospitals and NICUs that now use iNO has also increased; licensing and clinical pathways to make iNO available for use in the NICU are becoming more common‚ and the rate of use of iNO is increasing as health systems find it affordable and technically feasible․
- Rising Geriatric Population
The global growing geriatric population is the major driving factor for the global inhaled NO market growth since geriatric people have higher predisposition to hypertension‚ atherosclerosis‚ PAD‚ heart failure‚ and thrombosis for which inhaled NO is the preferred vasodilator․ According to the MDPI‚ 2024 heart failure prevalence increases from 1% in people under 55 years to more than 10% in people over 70 years of age․ COPD‚ pulmonary hypertension and ARDS are similar‚ where oxygen therapy is used․ In older patients‚ inhaled nitric oxide (iNO)‚ a strong pulmonary vasodilator‚ may be used to stimulate oxygenation and reduce pulmonary vascular resistance․ As people with the condition now live longer‚ the healthcare system must adapt to be able to meet their needs․
- Increasing Investments in Advanced Healthcare Infrastructure
Investment in advanced infrastructure of healthcare facilities will strengthen the inhaled nitric oxide market growth․ As per the official site of International Trade Administration (ITA) in 2024‚ India launched 5 new AIIMS facilities and introduced 202 other healthcare infrastructure projects in various states to drive healthcare technology developments in the country․ Because inhaled nitric oxide requires a specialized high-tech gas delivery system‚ healthcare facilities offering inhaled nitric oxide treatment generally include a neonatal intensive care unit‚ a specialized neonatal care unit or modern intensive care units with specialist equipment for treating hypoxic respiratory failure‚ pulmonary hypertension and ARDS in infants‚ children and adults․
Key Trends in the Inhaled Nitric Oxide Market
- Emergence of AI-Integrated Respiratory Monitoring Systems
AI is being used to optimize inhaled nitric oxide delivery using AI delivery devices with machine learning and patient data to automatically tailor the dose of inhaled nitric oxide and reduce side effects․ It would also improve clinical outcomes‚ by allowing providers to proactively intervene using predictive analytics to anticipate changes in the levels of oxygen saturation․ Companies are developing cloud-based inhalers for remote patient monitoring and management․ Hospitals use smart inhalation devices to ensure patients are treated correctly and not readmitted‚ and to integrate respiratory therapy with digital health technologies to improve safety for patients․
- Adoption of Eco-Friendly and Sustainable Gas Delivery Technologies
Sustainability in the inhaled nitric oxide market is a focus․ Next-generation delivery devices which meet international sustainability targets and benefit hospitals‚ including by reducing environmental impact of electronic and gas waste‚ are in development through integrated on-demand nitric oxide generation technology which avoids the carbon and logistical challenges of delivering pressurized nitric oxide gas cylinders․ Manufacturers are developing recycling‚ energy efficiency and provide a focus on small‚ green and portable technology․ It must have good clinical efficacy and low environmental impact․
- Growing Clinical Trials for Expanded Therapeutic Applications
Several other clinical trials are investigating the use of inhaled nitric oxide for additional indications‚ including acute respiratory distress syndrome (ARDS)‚ post cardiac surgery complications and as an adjunct therapy to treat infectious diseases․ The latter includes the use of inhaled nitric oxide for lung injury due to COVID-19 infection․ Furthermore‚ active pharmaceutical collaborations with universities are investigating the use of nitric oxide as a anti-inflammatory and vasodilator for additional indications․ As physicians become more familiar with the drug‚ its indications may broaden meaningfully to allow for the use of the drug in critical care and outpatient lung disease․
We explore the factors driving the growth of the market, including technological advancements, consumer behaviors, and regulatory changes, along with emerging inhaled nitric oxide market trends.
Leading Companies Operating in the Global Inhaled Nitric Oxide Industry:
- Air Liquide S.A
- Bellerophon Therapeutics
- Beyond Air Inc.
- Linde plc
- Mallinckrodt plc
- Merck KGaA
- Novoteris LLC
- Nu-Med Plus
- VERO Biotech LLC
Inhaled Nitric Oxide Market Report Segmentation:
Breakup by Application:
- Neonatal Respiratory Treatment
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Respiratory Distress Syndrome (ARDS)
- Others
Neonatal respiratory treatment held 86.1% of the market share in 2024 as it is the primary therapy for newborns with hypoxic respiratory failure and persistent pulmonary hypertension.
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America, accounting for 77.7%, enjoys the leading position in the market due to strong healthcare infrastructure, high prevalence of respiratory diseases, advanced research, and favorable regulatory policies.
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.
About Us:
Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@.com
Tel No: (D) +91 120 433 0800
United States: +1-201-971-6302
